Latest news and press releases about Quince Therapeutics, Inc. (QNCX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites.
Price
| Price | $27.17 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.43 |
| EV / EBITDA | 1.48 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -413.28% |
| Return on Invested Capital | -104.64% |
| Return on Assets | -74.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · ATYR · CAMP · CNTB · DTIL · GUTS
Explore sector: Healthcare · Biotechnology
More sections of QNCX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks